Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Paratek Pharmaceuticals Inc.

www.paratekpharm.com

Latest From Paratek Pharmaceuticals Inc.

Orphan AML Products Face CHMP Questioning

Companies developing new AML treatments are among those being called before the European Medicines Agency this week for questioning over marketing applications approaching the end of the review process. 

Europe Drug Review

Nabriva Faces Skepticism After Years Of Preparing For Novel Antibiotic Xenleta's Launch

Lefamulin was approved in the US to treat community-acquired bacterial pneumonia, providing a needed IV and oral drug initially in the hospital setting, but new antibiotics have been a tough sell.

Infectious Diseases Approvals

Finance Watch: Investment In Novel Antibacterials Gets A New Boost With Qpex Launch

Repeat antibiotic entrepreneurs raised $33m to launch Qpex with assets from The Medicines Co. Also, Taiho increases VC fund to $300m and TP Therapeutics raises $80m.

Financing StartUps and SMEs

QIDP Program Heads Into Uncomplicated Territory: Iterum, Paratek Eye uUTI Indications

Iterum’ssulopenem is first QIDP candidate to enter Phase III for uncomplicated urinary tract infection; Paratek’sNuzyra could be next.

Review Pathway Clinical Trials
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Infectious & Viral Diseases
  • Alias(es)
  • Transcept Pharmaceuticals Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Paratek Pharmaceuticals Inc.
  • Senior Management
  • Evan Loh, MD, CEO
    Douglas P Pagan, CFO
    Adam Woodrow, Pres. & Chief Commercial Officer
  • Contact Info
  • Paratek Pharmaceuticals Inc.
    Phone: (617) 807-6600
    75 Park Plaza, 4th Fl.
    Boston, MA 02116
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register